HAIC with immunotherapy and targeted drug for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three treatments for advanced liver cancer (BCLC stage C): HAIC (chemotherapy directly into the liver), adebrelimab (immunotherapy that helps your immune system fight cancer), and apatinib (a targeted drug that cuts off blood supply to tumors). It may be an option if you have not had any prior systemic (whole-body) therapy for liver cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hepatocellular carcinoma (a type of liver cancer).
- Your cancer has spread or is not removable by surgery, and you have not had any prior whole-body treatment for it.
- You are at least 18 years old.
- You can provide a small piece of your tumor tissue for testing.
- You have at least one measurable tumor on a scan.
- Your liver function is good enough (Child-Pugh class A or B).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
This Phase 2 trial studies whether delivering an immunotherapy drug directly into the liver’s artery, together with bevacizumab, can shrink advanced hepatocellular carcinoma. You may be considered if prior whole-body (systemic) treatment has not worked and prior local procedures were also not tolerated or failed.
This trial tests a combination of a targeted immunotherapy drug (ivonescimab) and a liver-directed chemotherapy infusion (HAIC) for people with liver cancer that cannot be removed by surgery. It may be an option if you have not had prior systemic treatment for your liver cancer.
This trial tests a combination of immunotherapy (iparomlimab/tuvonralimab), a targeted drug (bevacizumab), and radiation (SBRT) plus liver-directed chemo (HAIC) for people with advanced liver cancer (HCC) that has spread to blood vessels or a few other places. It aims to see if this approach can help control the cancer.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This trial tests a combination of three drugs—an immunotherapy (TQB2450), a targeted therapy (anlotinib), and a repeat HAIC infusion—for people whose advanced liver cancer has worsened after a first treatment. It may be an option if you've already had HAIC with platinum and are now looking for a new approach.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.